Focus on Pancreatic Cancer
Nearly one-third of participants in the FOLFIRINOX arm of the trial had some tumor shrinkage.
A four-drug chemotherapy regimen has produced the longest improvement in survival ever seen in a phase III clinical trial of people with metastatic pancreatic cancer, one of the deadliest types of cancer.
Pancreatic cancer develops and spreads much more slowly than scientists have thought, according to new research from Johns Hopkins investigators. The finding indicates that there is a potentially broad window for diagnosis and prevention of the disease.
In a clinical trial testing an experimental enzyme regimen against gemcitabine-based chemotherapy for advanced pancreatic cancer, people receiving chemotherapy lived an average of 9.7 months longer. The results are published in the Journal of Clinical Oncology.